Charles Wolfus
Chief Tech/Sci/R&D Officer en ALECTOR, INC. .
Perfil
Charles Wolfus is currently the VP-Technology & Digital Health at Alector, Inc. He was previously the Director-Global IT Infrastructure & Operations at Onyx Pharmaceuticals, Inc. from 2011 to 2014 and the VP-Digital Health & Business Operations at MyoKardia, Inc. from 2014 to 2019.
He has an undergraduate degree from the University of California San Diego and a graduate degree from California Western School of Law.
Cargos activos de Charles Wolfus
| Empresas | Cargo | Inicio |
|---|---|---|
| ALECTOR, INC. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
Antiguos cargos conocidos de Charles Wolfus.
| Empresas | Cargo | Fin |
|---|---|---|
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/01/2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/01/2014 |
Formación de Charles Wolfus.
| University of California San Diego | Undergraduate Degree |
| California Western School of Law | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ALECTOR, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Charles Wolfus
